Alnylam Pharmaceuticals, Inc.
TMPRSS6 iRNA compositions and methods of use thereof

Last updated:

Abstract:

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as .beta.-thalassemia or hemochromatosis.

Status:
Grant
Type:

Utility

Filling date:

15 Nov 2018

Issue date:

9 Feb 2021